Stepped Care for Youth at Risk of Psychosis

Clinical High Risk for Developing Psychosis Clinical Trial

Official title:

A Framework for Research in Emerging Adults: Stepped Care for Youth at Risk of Psychosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04829292
• Other study ID #: ACH Foundation
• Status: Recruiting
• Phase: N/A
• Start date: September 1, 2021
• Est. completion date: April 30, 2026

Study information

• Verified date: June 2023
• Source: University of Calgary
• Contact: Monica Chu
• Phone: 403-210-8737
• Email: mochu[@]ucalgary.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will recruit 60 young people who meet established criteria for being at clinical high risk for psychosis. They will be offered a range of psychological interventions starting with the most benign treatments in different steps. At step 1 they will be offered individual or group support and if there is no improvement they will be offered more intensive CBT individual therapy or CBSST group therapy. Assessments will occur at baseline, 6,12 and 18 months

Description:

In treating youth at clinical high risk of developing psychosis we have not been able to address what treatment to offer first and when to offer more intense and, ultimately, more costly treatments. The goals of achieving Precision Health objectives require that these questions be addressed through research. The overall aim is to determine the most effective and efficient way to offer active and maintenance treatment resources for CHR youth. The first step would be to offer a range of treatments starting with the most benign as advocated in the McGorry and Hickie stage model. We will use this project to test whether clinical staging will improve prediction of prognosis and result in improved matching of treatment. The specific objectives of this project are: (1) to determine which and what proportion of participants would remit (i) within the first 1-2 months of treatment, (ii) after a brief supportive therapy, (iii) after longer term, focused psychological interventions such as CBT, CBSST and family intervention and (iv) how many make use of medications; (2) to determine adherence of CHR individuals to different treatments; and (3) to determine the need for maintenance treatment. To assess these objectives the following outcomes will be determined: 1. Improvement of Attenuated Psychotic Symptoms 2. Improved social functioning as rated by Global: Social Functioning 3. Percentage of the sample that demonstrate either symptomatic or functional improvement after Step 1 treatments and do not require to move to Step 2 treatments. 4. Percentage of sample that move to Step 2 Treatments and the percentage that achieve improvement in either symptoms or functioning. 5. Percentage of participants allocated to a given treatment that adhere to the treatment. Participants will be between ages 13 and 25. We will recruit 60 participants who meet well-established criteria for clinical high risk for psychosis based on the Structured Interview for Psychosis-Risk Syndromes (SIPS). Assessments will be conducted at baseline and 2, 6, 12, and 18 months after baseline. Assessments consist of clinical assessments. Clinical raters will be experienced raters and will be trained on all clinical measures and routine reliability checks will be conducted.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: April 30, 2026
• Est. primary completion date: April 30, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 13 Years to 25 Years

Eligibility

Inclusion Criteria:

• Meeting SIPS criteria for clinical high risk for psychosis

Exclusion Criteria:

• meeting criteria for any current or past axis I psychotic disorder, IQ less than 70, or past or current history of a clinically significant central nervous system disorder.

Related Conditions & MeSH terms

• Clinical High Risk for Developing Psychosis
• Mental Disorders
• Psychotic Disorders

Intervention

Behavioral:
• Supportive therapy and CBT
In this open trial participants are first offered supportive therapy followed by CBT

Locations

Country	Name	City	State
Canada	Mathison Centre for Research and Education, University of Calgary	Calgary	Alberta

Sponsors (1)

Lead Sponsor	Collaborator
University of Calgary

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Scale of Psychosis Risk Symptoms	Individuals' clinical symptoms will be measured using scores on positive symptoms on the SOPS.	Baseline and 18 months
Secondary	Global Functioning Scale: Social and Role	Clinical rating scales to assess if there are changes in social and role functioning.	Baseline and 18 months